Breaking: New PolyBio-supported Study Identifies Microclots, Endothelial Injury Markers and Neutrophil Activation in Children and Young Adults with Long COVID
A new study supported by PolyBio Research Foundation studied children and young adults with Long COVID, providing evidence linking endovascular inflammation, increased quantity and size of fibrin-amyloid “microclots,” and neutrophil activation, and finding detectable Spike protein in a subset. polybio.org/new-study-poly…
2/ Published in Pediatric Research, the study helps clarify the biological basis of cardiovascular symptoms in an important but understudied Long COVID population, and advances scientific insights that will support future diagnostic development.
3/ “Given that children and adults can have significantly different responses to acute COVID-19 illness, it’s important to study, understand, and document Long COVID-related biological changes in children and young adults,” said Michael VanElzakker PhD, PolyBio co-founder, neuroscientist at Massachusetts General Hospital/Harvard Medical School, and an author on the study.
4/ The study investigators enrolled 84 children and young adults from the United States and Canada, including 61 participants with Long COVID and 23 healthy pediatric controls, and analyzed symptom burden alongside blood-based markers of vascular dysfunction.
5/ From the paper: Children and young adults with long COVID have altered levels and strong associations between circulating endovascular-associated cytokines. a Correlation matrix between 32 endothelial cytokines in Long COVID patients.
6/ The team found that participants with Long COVID had a significantly increased burden of fibrin amyloid microclots in the blood. They also observed abnormal endothelial signaling, including increased markers of angiogenesis and vascular remodeling such as FGF-2, which correlated with microclot burden.
7/ At the same time, cell-free DNA – a marker consistent with intravascular neutrophil extracellular trap formation, or NETosis – was elevated and positively correlated with serum amyloid A, a component of microclots. FGF-2, a cytokine involved in angiogenesis and wound healing, was significantly increased in Spike-positive versus Spike-negative patients.
8/ Importantly, the study went beyond correlation. In vitro co-culture assays showed that SARS-CoV-2 Spike protein immune complexes can trigger NETosis, which in turn contributes to endothelial injury. Taken together, the findings suggest that intravascular neutrophil activation may be a key driver of endovascular pathology in Long COVID.
9/ The pediatric and young adult focus of the study is especially important. Because younger individuals are less likely to have the cardiometabolic and inflammatory comorbidities that often complicate interpretation in older adult cohorts, these findings strengthen the case that microclots and endothelial abnormalities are directly related to Long COVID biology rather than background age-related disease.
10/ The team proposes that a combination of microclots, neutrophil markers, endothelial cytokines, and potentially circulating Spike protein could serve as biomarkers for Long COVID – an advance that could help support more rigorous diagnosis, patient stratification, and assessment of therapeutic response in future studies.
11/ For PolyBio, the study underscores a central principle: Long COVID is not a vague syndrome but a condition with measurable biological drivers. By supporting work that identifies objective markers of disease, PolyBio is helping build the scientific foundation for the next generation of Long COVID diagnostics and targeted clinical trials.
Mount Sinai’s CoRE Clinic is recruiting participants for a clinical trial of low-dose Rapamycin for Long COVID. The major focus of this trial is to determine which LC patient subtypes benefit most from the drug. Your participation will help researchers better understand targeted immune modulating therapies for infection-associated chronic illnesses.
More information & eligibility details👇🏻
2/ Low-dose Rapamycin is being investigated for its potential to reduce viral activity associated with persistent SARS-CoV-2, EBV or other viruses implicated in Long COVID. The trial is structured to safely and gradually increase the drug’s dose to 4 mg once a week in the treatment group.
3/ Now, with the addition of an open-label phase, participants can opt to receive the drug after the 3 month trial period is completed—even if they were initially randomized to placebo.
Dr. Henry Van Brocklin and his UCSF team are investigating the novel radiotracer [18F]F-AraG as a biomarker of long-term immune dysregulation in Long COVID. When paired with PET imaging, the tracer has shown persistent T cell activation in tissues such as the brain, lungs, gut, spinal cord & bone marrow.
“Even in cases where the Long COVID symptoms were not associated with the [organ] phenotype, we actually saw elevation there,” said Van Brocklin. The method is actively being tested in a clinical trial of Ensitrelvir for Long COVID to determine measurable changes in immune activation following treatment versus placebo.
PolyBio is supporting this multimodal PET study, which combines the team’s novel imaging technique with gut biopsy analyses to assess tissue-based inflammation across the entire body in Long COVID. The technique has previously been applied in a study of the monoclonal antibody AER002 within the PolyBio-supported LIINC cohort; demonstrating changes to inflammation across various tissue sites pre- and post-treatment. 2/
The team is continuing to validate T cell activation via [18F]F-AraG as a potential biomarker of inflammation in clinical trials within PolyBio’s network, including the current UCSF-based trial of Ensitrelvir for Long COVID. This research will help determine the degree to which the therapeutics are successfully lowering Long COVID-associated inflammation. 3/
Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Rapamycin Trial
PolyBio today announced new funding that is supporting an open-label extension phase in a clinical trial investigating low-dose Rapamycin as a potential treatment for Long COVID. All participants—including those initially randomized to placebo—will receive low-dose rapamycin during a defined follow-up period. 1/
This approach is expected to improve willingness to enrol while preserving the rigor of the randomized controlled phase of the trial. The support will also allow study coordinators to conduct home visits for certain participants to collect blood samples, helping expand access for individuals who are too ill or geographically constrained to consistently travel to study sites. 2/
“Vitalik and the Balvi Fund have been incredible supporters of both PolyBio and the broader Long COVID research space over the years,” said Dr. Amy Proal, President of PolyBio Research Foundation. 3/
Follow along with the #polybiospringsymposium2026 in this thread👇🏻
11:00 am ET—Dr. Amy Proal kicked off this Spring symposium with an overview of PolyBio’s new commercialization network that will help translate Long COVID biomarkers from the lab & therapies from coordinated clinical trials into useful tools in the clinic. She also discussed how this commercialization infrastructure can be applied to other IACIs.
11:10 am ET—Resia Pretorius discussed several new papers that help establish the process of microclot formation in Long COVID & Post-Vaccination Syndrome. One study demonstrated variable proteomic clotting-related signatures between LC & PVS, including inverted PF4 & S100-A9 levels between the conditions.
11:20 am—Marcus Buggert discussed a longitudinal study in Long COVID patients tracking inflammatory & immune cell changes over time. The new data shows increased interferon signalling that was most elevated in the sigmoid colon, likely linking to SCV2 gut persistence. The data also showed a reduction in TGF-beta production in the T & B cells of Long COVID patients, indicating persistent immune dysregulation.
Breaking: Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative
PolyBio Research Foundation today announced a $10M donation to support the Long COVID Cure Initiative (LCCI), a program designed to deliver treatments to millions of Long COVID patients by translating key academic findings into real-world diagnostic tests, faster and more targeted clinical trials, and accessible, patient-ready therapies. prnewswire.com/news-releases/…
2/ Funding was provided by the Park-Pagliuca Fund, a philanthropic collaboration between the families of Todd Park and Steve Pagliuca, each of whom have family members impacted by Long COVID.
3/ The Bottleneck: Translation, Not Discovery
Long COVID has left hundreds of millions worldwide with debilitating fatigue, neurological dysfunction, and increased health risks including heart attack and stroke. In the United States alone, the condition is estimated to cost trillions of dollars and has pushed millions of people out of the workforce.
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group showed elevated MMPs & cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
2/ Researchers also found altered cytokine interactions, including disrupted fractalkine and eotaxin pathways, which may drive neuroinflammation and cognitive symptoms.
3/ PolyBio also awarded $1M to UCSF to expand the LIINC program into ME/CFS, using tissue biopsy and advanced ImmunoPET-CT imaging to study viral persistence and immune activation in the brain, spinal cord, and bone marrow.